Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases

 Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases

Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases

Shots:

  • Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones related to licensed products including 2 undisclosed Pfizer’s transgenes along with royalties based on sales of products including licensed capsids
  • Pfizer gets the right to assess novel capsids for CNS & cardiac tropisms by utilizing Voyager’s TRACER platform & exercise its options to license capsids for exclusive use in its AAV gene therapies including 2 transgenes
  • Voyager holds global rights for all licensed capsids to use with other transgenes & applications of its TRACER technology

Click here to read full press release/ article | Ref: Voyager Therapeutics | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post